Low Risk, High Risk: Adjuvant Therapy in Resected p16+ Oropharyngeal Cancer with ≥5 Positive Ipsilateral Lymph Nodes

Int J Radiat Oncol Biol Phys. 2022 Sep 1;114(1):10-11. doi: 10.1016/j.ijrobp.2022.04.018.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Combined Modality Therapy
  • Humans
  • Lymph Nodes / pathology
  • Oropharyngeal Neoplasms* / pathology
  • Oropharyngeal Neoplasms* / therapy
  • Papillomaviridae